Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, First-in-human, Phase Ib/II Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of COR-101 in Hospitalized Patients
Latest Information Update: 07 May 2024
At a glance
- Drugs COR 101 (Primary)
- Indications COVID-19 respiratory infection; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Corat Therapeutics
- 17 Feb 2023 This trial has been discontinued in Germany (End Date: 23 Jan 2023) according to European Clinical Trials Database record.
- 13 Feb 2023 This trial has been discontinued in Bulgaria.
- 24 May 2022 Planned End Date changed from 30 Oct 2021 to 30 Oct 2022.